Rosalie Liccardo Pacula — Publications

America's Opioid Ecosystem: How Leveraging System Interactions Can Help Curb Addiction, Overdose, and Other Harms 2023
The Ecosystem Approach to Opioid Policy 2023
How Much Can You Trust the Results of This Health Policy Evaluation: A Pragmatic Guide for State Policymakers 2023
Cannabis Legalization and Cannabis-Involved Pregnancy Hospitalizations in Colorado 2022
Comparison of Hospital Claims and Poison Center Data to Evaluate Health Impact of Opioids, Cannabis and Synthetic Cannabinoids 2022
The Effect of State Policies on Rates of High-Risk Prescribing of an Initial Opioid Analgesic 2022
Expert Panel Consensus on State-Level Policies to Improve Engagement and Retention in Treatment for Opioid Use Disorder 2022
Trends in Out-of-Pocket Costs for Naloxone by Drug Brand and Payer in the US, 2010–2018 2022
APCDs Can Provide Important Insights for Surveilling the Opioid Epidemic, With Caveats 2021
Assessment of State and Federal Health Policies for Opioid Use Disorder Treatment During the COVID-19 Pandemic and Beyond 2021
Changes in Emergency Department Encounters for Vomiting After Cannabis Legalization in Colorado 2021
Claims-based Measures of Prescription Opioid Utilization: A Practical Guide for Researchers 2021
Current U.S. State Cannabis Sales Limits Allow Large Doses for Use or Diversion 2021
The Evolving Consequences of OxyContin Reformulation on Drug Overdoses 2021
Mental Health Conditions and Substance Use Disorders Among Youth Subsequently Diagnosed With Opioid Use Disorder or Opioid Poisoning 2021
Moving Beyond the Classic Difference-In-Differences Model: A Simulation Study Comparing Statistical Methods for Estimating Effectiveness of State-Level Policies 2021
How Increasing Medical Access to Opioids Contributes to the Opioid Epidemic: Evidence from Medicare Part D 2020
Pitfalls and Potholes: Data Issues to Consider When Analyzing State Opioid Policies, September 14, 2020 2020
State Approaches to Tackling the Opioid Crisis Through the Health Care System 2020
The State of the Science in Opioid Policy Research 2020
Association Between State Laws Facilitating Pharmacy Distribution of Naloxone and Risk of Fatal Overdose 2019
Early Evidence of the Impact of Cannabis Legalization on Cannabis Use, Cannabis Use Disorder, and the Use of Other Substances: Findings from State Policy Evaluations 2019
The Synthetic Opioid Surge in the United States: Insights from Mortality and Seizure Data 2019
A Transitioning Epidemic: How The Opioid Crisis Is Driving The Rise In Hepatitis C 2019
Do Medical Marijuana Laws Reduce Addictions and Deaths Related to Pain Killers? 2018
Marijuana Buyers in the United States, 2010–2014 2018
Medical Marijuana Laws and Adolescent Marijuana Use in the United States: A Systematic Review and Meta-Analysis 2018
A Population-Based Examination of Trends and Disparities in Medication Treatment for Opioid Use Disorders Among Medicaid Enrollees 2018
Supply-Side Drug Policy in the Presence of Substitutes: Evidence from the Introduction of Abuse-Deterrent Opioids 2018
A Supply-Side Perspective on the Opioid Crisis 2018
Advancing Knowledge on Cannabis Policy Using Evidence from North America 2017
Association of State Recreational Marijuana Laws with Adolescent Marijuana Use 2017
Did the Dependent Coverage Expansion Increase Risky Substance Use Among Young Adults? 2017
Early Impacts of Marijuana Legalization: An Evaluation of Prices in Colorado and Washington 2017
Funding Considerations in the Fight Against the Opioid Epidemic: What the Science Tells Us 2017
Medical Marijuana and Marijuana Legalization 2017
Regulating Medical Marijuana Markets: Insights from Scientific Evaluations of State Experiments 2017
Supply-Side Drug Policy in the Presence of Substitutes: Evidence from the Introduction of Abuse-Deterrent Opioids 2017
Understanding and Learning from the Diversification of Cannabis Supply Laws 2017
In the Weeds: A Baseline View of Cannabis Use Among Legalizing States and Their Neighbours 2016
Opioid Analgesic and Benzodiazepine Prescribing Among Medicaid-enrollees with Opioid Use Disorders: The Influence of Provider Communities 2016
Physician Capacity to Treat Opioid Use Disorder with Buprenorphine-Assisted Treatment 2016
Preventing, Identifying, and Treating Prescription Drug Misuse Among Active-Duty Service Members 2016
A Systematic Review of the Prevention and Treatment of Prescription Drug Misuse 2016
Assessing the Effects of Medical Marijuana Laws on Marijuana Use: The Devil Is in the Details 2015
Considering Marijuana Legalization: Insights for Vermont and Other Jurisdictions 2015
Growth in Buprenorphine Waivers for Physicians Increased Potential Access to Opioid Agonist Treatment, 2002-11 2015
The Marijuana Legalization Debate: Insights for Vermont 2015
Medical Marijuana Laws and Adolescent Marijuana Use in the USA from 1991 to 2014: Results from Annual, Repeated Cross-Sectional Surveys 2015
More Choice in Health Insurance Marketplaces May Reduce the Value of the Subsidies Available to Low-Income Enrollees 2015
Options and Issues Regarding Marijuana Legalization 2015
Policies Related to Opioid Agonist Therapy for Opioid Use Disorders: The Evolution of State Policies from 2004 to 2013 2015
Policies to Support a Better Treatment for Heroin and Prescription Opioid Abuse: Unlike Methadone, Buprenorphine Can Be Taken at Home, but Greater Access is Key 2015
Supply of Buprenorphine Waivered Physicians: The Influence of State Policies 2015
Where Is Buprenorphine Dispensed to Treat Opioid Use Disorders? The Role of Private Offices, Opioid Treatment Programs, and Substance Abuse Treatment Facilities in Urban and Rural Counties 2015
Cannabis Use and Antisocial Behavior Among Youth 2014
Decomposing Racial Disparities in Prison and Drug Treatment Commitments for Criminal Offenders in California 2014
Developing Public Health Regulations for Marijuana: Lessons from Alcohol and Tobacco 2014
The Effects of Medical Marijuana Laws on Potency 2014
How Big Is the U.S. Market for Illegal Drugs? 2014
Marijuana Liberalization Policies: Why We Can't Learn Much from Policy Still in Motion 2014
Natural Experiments in a Complex and Dynamic Environment: The Need for a Measured Assessment of the Evidence 2014
What America's Users Spend on Illegal Drugs: 2000–2010 2014
Why Changes in Price Matter When Thinking About Marijuana Policy: A Review of the Literature on the Elasticity of Demand 2014
Words Can Be Deceiving: A Review of Variation Among Legally Effective Medical Marijuana Laws in the United States 2014
Before the Grand Opening: Measuring Washington State's Marijuana Market in the Last Year Before Legalized Commercial Sales 2013
Developing Public Health Regulations for Legal Marijuana 2013
Design Considerations for Legalizing Cannabis: Lessons Inspired by Analysis of California's Proposition 19 2012
Epidemiological Model for Examining Marijuana Use Over the Life Course 2012
Measuring IPR infringements in the internal market: Development of a new approach to estimating the impact of infringements on sales 2012
A Search-Theoretic Model of the Retail Market for Illicit Drugs 2012
The U.S. Drug Policy Landscape: Insights and Opportunities for Improving the View 2012
Addiction Research Centres and the Nurturing of Creativity: RAND's Drug Policy Research Center 2011
An Analysis of Applicants Presenting to a Medical Marijuana Specialty Practice in California 2011
Bringing Perspective to Illicit Markets: Estimating the Size of the U.S. Marijuana Market 2011
Heterogeneity in the Composition of Marijuana Seized in California 2011
Invisible Wounds, Visible Savings? Using Microsimulation to Estimate the Costs and Savings Associated with Providing Evidence-Based Treatment for PTSD and Depression to Veterans of Operation Enduring Freedom and Operation Iraqi Freedom 2011
Substance Use and Recessions: What Can Be Learned from Economic Analyses of Alcohol? 2011
What Is the Impact of Using Evidence-Based Treatments for Posttraumatic Stress Disorder and Depression in Veterans? 2011
Altered State? Assessing How Marijuana Legalization in California Could Influence Marijuana Consumption and Public Budgets 2010
An Assessment of the Scientific Support Underlying the FY2011 Budget Priorities of the Office of National Drug Control Policy 2010
Examining the Impact of Marijuana Legalization on Harms Associated with Marijuana Use 2010
Examining the Impact of Marijuana Legalization on Marijuana Consumption: Insights from the Economics Literature 2010
How Might Marijuana Legalization in California Affect Public Budgets and Marijuana Consumption? 2010
Marijuana Use and High School Dropout: The Influence of Unobservables 2010
Preventing Drug Use 2010
Risks and Prices: The Role of User Sanctions in Marijuana Markets 2010
Tackling problem drug use 2010
Assessing Changes in Global Drug Problems, 1998-2007: Main Report 2009
The Costs of Methamphetamine Use: A National Estimate 2009
Do Citizens Know Whether Their State Has Decriminalized Marijuana? Assessing the Perceptual Component of Deterrence Theory 2009
The Economic Cost of Methamphetamine Use in the United States, 2005 2009
Estimating the size of the global drug market: A demand-side approach: Report 2 2009
Issues in estimating the economic cost of drug abuse in consuming nations: Report 3 2009
Legalizing Marijuana: Issues to Consider Before Reforming California State Law 2009
The Incremental Inpatient Costs Associated with Marijuana Comorbidity 2008
Invisible Wounds of War: Psychological and Cognitive Injuries, Their Consequences, and Services to Assist Recovery 2008
Marijuana Use and High School Dropout: The Influence of Unobservables 2008
What Research Tells Us About the Reasonableness of the Current Priorities of National Drug Control 2008
Risks and Prices: The Role of User Sanctions in Marijuana Markets 2007
College Students' Use of Cocaine 2006
Is the Drug Court Model Exportable? The Cost-Effectiveness of a Driving-Under-The-Influence Court 2006
Marijuana Markets: Inferences from Reports by the Household Population 2006
Racial Differences in Marijuana-Users' Risk of Arrest in the United States 2006
Alcohol and Marijuana Use Among College Students: Economic Complements or Substitutes? 2004
Does Marijuana Use Impair Human Capital Formation? 2004
Marijuana and Crime: Is There a Connection Beyond Prohibition? 2004
Marijuana Decriminalization: What Does it Mean in the United States? 2004
What We Can--And Cannot--Expect from School-Based Drug Prevention 2004
Cannabis Use and Dependence: Public Health and Public Policy 2003
Does Marijuana Use Impair Human Capital Formation? 2003
How State Medical Marijuana Laws Vary: A Comprehensive Review 2003
The Relationship Between Cigarette Use and Other Tobacco Products: Results from the 2000 National Youth Tobacco Survey 2003
School-Based Drug Prevention: What Kind of Drug Use Does It Prevent? 2002
State Medical Marijuana Laws: Understanding the Laws and Their Limitations 2002
What Are the True Benefits of School-Based Drug Prevention Programs? 2002
Does the Sunset of Mental Health Parity Really Matter? 2001
Economics of Youth Drug Use, Addiction and Gateway Effects 2001
The Effects of Macro-Level Interventions on Addictive Behavior 2001
The Impact of Prices and Control Policies on Cigarette Smoking Among College Students 2001
Marijuana and Youth 2001
Are People With Mental Illness Getting the Help They Need? New Findings About Parity Laws, Insurance Coverage, and Access to Care 2000
Economics and Antihealth Behavior: The Economic Analysis of Substance Use and Abuse 2000
Mental Health Parity and Employer-Sponsored Health Insurance in 1999-2000 2000
Mental Health Parity and Employer-Sponsored Health Insurance in 1999-2000 2000
Mental Health Parity Legislation: Much Ado About Nothing? 2000
State Mental Health Parity Laws: Cause Or Consequence Of Differences In Use? 2000
Labor Force Participation by Persons with Mental Illness 1999
Sex and Race Differences in Young People's Responsiveness to Price and Tobacco Control Policies 1999
Economic Modelling of the Gateway Effect 1997

Rosalie Liccardo Pacula — Publications

America's Opioid Ecosystem: How Leveraging System Interactions Can Help Curb Addiction, Overdose, and Other Harms 2023

The Ecosystem Approach to Opioid Policy 2023

How Much Can You Trust the Results of This Health Policy Evaluation: A Pragmatic Guide for State Policymakers 2023

Cannabis Legalization and Cannabis-Involved Pregnancy Hospitalizations in Colorado 2022

Comparison of Hospital Claims and Poison Center Data to Evaluate Health Impact of Opioids, Cannabis and Synthetic Cannabinoids 2022

The Effect of State Policies on Rates of High-Risk Prescribing of an Initial Opioid Analgesic 2022

Expert Panel Consensus on State-Level Policies to Improve Engagement and Retention in Treatment for Opioid Use Disorder 2022

Trends in Out-of-Pocket Costs for Naloxone by Drug Brand and Payer in the US, 2010–2018 2022

APCDs Can Provide Important Insights for Surveilling the Opioid Epidemic, With Caveats 2021

Assessment of State and Federal Health Policies for Opioid Use Disorder Treatment During the COVID-19 Pandemic and Beyond 2021

Changes in Emergency Department Encounters for Vomiting After Cannabis Legalization in Colorado 2021

Claims-based Measures of Prescription Opioid Utilization: A Practical Guide for Researchers 2021

Current U.S. State Cannabis Sales Limits Allow Large Doses for Use or Diversion 2021

The Evolving Consequences of OxyContin Reformulation on Drug Overdoses 2021

Mental Health Conditions and Substance Use Disorders Among Youth Subsequently Diagnosed With Opioid Use Disorder or Opioid Poisoning 2021

Moving Beyond the Classic Difference-In-Differences Model: A Simulation Study Comparing Statistical Methods for Estimating Effectiveness of State-Level Policies 2021

How Increasing Medical Access to Opioids Contributes to the Opioid Epidemic: Evidence from Medicare Part D 2020

Pitfalls and Potholes: Data Issues to Consider When Analyzing State Opioid Policies, September 14, 2020 2020

State Approaches to Tackling the Opioid Crisis Through the Health Care System 2020

The State of the Science in Opioid Policy Research 2020

Association Between State Laws Facilitating Pharmacy Distribution of Naloxone and Risk of Fatal Overdose 2019

Early Evidence of the Impact of Cannabis Legalization on Cannabis Use, Cannabis Use Disorder, and the Use of Other Substances: Findings from State Policy Evaluations 2019

The Synthetic Opioid Surge in the United States: Insights from Mortality and Seizure Data 2019

A Transitioning Epidemic: How The Opioid Crisis Is Driving The Rise In Hepatitis C 2019

Do Medical Marijuana Laws Reduce Addictions and Deaths Related to Pain Killers? 2018

Marijuana Buyers in the United States, 2010–2014 2018

Medical Marijuana Laws and Adolescent Marijuana Use in the United States: A Systematic Review and Meta-Analysis 2018

A Population-Based Examination of Trends and Disparities in Medication Treatment for Opioid Use Disorders Among Medicaid Enrollees 2018

Supply-Side Drug Policy in the Presence of Substitutes: Evidence from the Introduction of Abuse-Deterrent Opioids 2018

A Supply-Side Perspective on the Opioid Crisis 2018

Advancing Knowledge on Cannabis Policy Using Evidence from North America 2017

Association of State Recreational Marijuana Laws with Adolescent Marijuana Use 2017

Did the Dependent Coverage Expansion Increase Risky Substance Use Among Young Adults? 2017

Early Impacts of Marijuana Legalization: An Evaluation of Prices in Colorado and Washington 2017

Funding Considerations in the Fight Against the Opioid Epidemic: What the Science Tells Us 2017

Medical Marijuana and Marijuana Legalization 2017

Regulating Medical Marijuana Markets: Insights from Scientific Evaluations of State Experiments 2017

Supply-Side Drug Policy in the Presence of Substitutes: Evidence from the Introduction of Abuse-Deterrent Opioids 2017

Understanding and Learning from the Diversification of Cannabis Supply Laws 2017

In the Weeds: A Baseline View of Cannabis Use Among Legalizing States and Their Neighbours 2016

Opioid Analgesic and Benzodiazepine Prescribing Among Medicaid-enrollees with Opioid Use Disorders: The Influence of Provider Communities 2016

Physician Capacity to Treat Opioid Use Disorder with Buprenorphine-Assisted Treatment 2016

Preventing, Identifying, and Treating Prescription Drug Misuse Among Active-Duty Service Members 2016

A Systematic Review of the Prevention and Treatment of Prescription Drug Misuse 2016

Assessing the Effects of Medical Marijuana Laws on Marijuana Use: The Devil Is in the Details 2015

Considering Marijuana Legalization: Insights for Vermont and Other Jurisdictions 2015

Growth in Buprenorphine Waivers for Physicians Increased Potential Access to Opioid Agonist Treatment, 2002-11 2015

The Marijuana Legalization Debate: Insights for Vermont 2015

Medical Marijuana Laws and Adolescent Marijuana Use in the USA from 1991 to 2014: Results from Annual, Repeated Cross-Sectional Surveys 2015

More Choice in Health Insurance Marketplaces May Reduce the Value of the Subsidies Available to Low-Income Enrollees 2015

Options and Issues Regarding Marijuana Legalization 2015

Policies Related to Opioid Agonist Therapy for Opioid Use Disorders: The Evolution of State Policies from 2004 to 2013 2015

Policies to Support a Better Treatment for Heroin and Prescription Opioid Abuse: Unlike Methadone, Buprenorphine Can Be Taken at Home, but Greater Access is Key 2015

Supply of Buprenorphine Waivered Physicians: The Influence of State Policies 2015

Where Is Buprenorphine Dispensed to Treat Opioid Use Disorders? The Role of Private Offices, Opioid Treatment Programs, and Substance Abuse Treatment Facilities in Urban and Rural Counties 2015

Cannabis Use and Antisocial Behavior Among Youth 2014

Decomposing Racial Disparities in Prison and Drug Treatment Commitments for Criminal Offenders in California 2014

Developing Public Health Regulations for Marijuana: Lessons from Alcohol and Tobacco 2014

The Effects of Medical Marijuana Laws on Potency 2014

How Big Is the U.S. Market for Illegal Drugs? 2014

Marijuana Liberalization Policies: Why We Can't Learn Much from Policy Still in Motion 2014

Natural Experiments in a Complex and Dynamic Environment: The Need for a Measured Assessment of the Evidence 2014

What America's Users Spend on Illegal Drugs: 2000–2010 2014

Why Changes in Price Matter When Thinking About Marijuana Policy: A Review of the Literature on the Elasticity of Demand 2014

Words Can Be Deceiving: A Review of Variation Among Legally Effective Medical Marijuana Laws in the United States 2014

Before the Grand Opening: Measuring Washington State's Marijuana Market in the Last Year Before Legalized Commercial Sales 2013

Developing Public Health Regulations for Legal Marijuana 2013

Design Considerations for Legalizing Cannabis: Lessons Inspired by Analysis of California's Proposition 19 2012

Epidemiological Model for Examining Marijuana Use Over the Life Course 2012

Measuring IPR infringements in the internal market: Development of a new approach to estimating the impact of infringements on sales 2012

A Search-Theoretic Model of the Retail Market for Illicit Drugs 2012

The U.S. Drug Policy Landscape: Insights and Opportunities for Improving the View 2012

Addiction Research Centres and the Nurturing of Creativity: RAND's Drug Policy Research Center 2011

An Analysis of Applicants Presenting to a Medical Marijuana Specialty Practice in California 2011

Bringing Perspective to Illicit Markets: Estimating the Size of the U.S. Marijuana Market 2011

Heterogeneity in the Composition of Marijuana Seized in California 2011

Invisible Wounds, Visible Savings? Using Microsimulation to Estimate the Costs and Savings Associated with Providing Evidence-Based Treatment for PTSD and Depression to Veterans of Operation Enduring Freedom and Operation Iraqi Freedom 2011

Substance Use and Recessions: What Can Be Learned from Economic Analyses of Alcohol? 2011

What Is the Impact of Using Evidence-Based Treatments for Posttraumatic Stress Disorder and Depression in Veterans? 2011